Notable Reporting: Time to Buy Nabriva Therapeutics AG – ADR After Making Yearly Low?

Notable Reporting: Time to Buy Nabriva Therapeutics AG   ADR After Making Yearly Low?

The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) hit a new 52-week low and has $6.01 target or 10.00% below today’s $6.68 share price. The 9 months bearish chart indicates high risk for the $142.85M company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $6.01 price target is reached, the company will be worth $14.29 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 15,546 shares traded hands or 8.42% up from the average. Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has declined 22.36% since March 14, 2016 and is downtrending. It has underperformed by 27.97% the S&P500.

Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) Ratings Coverage

Out of 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nabriva Therapeutics has been the topic of 6 analyst reports since October 12, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Gabelli on Wednesday, January 27. The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) earned “Outperform” rating by RBC Capital Markets on Tuesday, October 13. Needham initiated the stock with “Buy” rating in Monday, October 12 report. The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) earned “Outperform” rating by Leerink Swann on Tuesday, October 13. The stock has “Outperform” rating given by RBC Capital Markets on Thursday, November 12. On Tuesday, October 13 the stock rating was initiated by Wedbush with “Outperform”.

According to Zacks Investment Research, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.”

More news for Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) were recently published by: Benzinga.com, which released: “Leerink: Time To Buy Nabriva Therapeutics’ ‘Unique Differentiation'” on October 13, 2015. Marketwatch.com‘s article titled: “Some ‘cheap’ biotech stocks that could be buyout targets, RBC says” and published on January 25, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment